BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 9, 2005--Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today announced the scheduled presentation of an abstract at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on the application of the Company's TOCOSOL(R) technology to a new camptothecin derivative. Camptothecins are a rapidly growing class of anti-cancer drugs that are currently used in the treatment of colon, lung and ovarian cancers. The AACR-NCI-EORTC conference is being held November 14-18 at the Pennsylvania Convention Center in Philadelphia.
